"A Clinical Study to Evaluate the Effectiveness of Beltavac® with polymerized extract of grass pollen mixture in allergic rhinoconjunctivitis in patients with allergic rhinoconjunctivitis associated or not with asthma"

Overview

Sponsor-declared trial summary

Key facts

Sponsor

Probelte Pharma S.L.

Participant type

Patients

Age range

18-64 years, 65+ years

Gender

Male and Female

Therapeutic area

Diseases [C] - Disorders of Environmental Origin [C21], Diseases [C] - Eye Diseases [C11]

Decision date (initial)

2025-06-16

Transition trial

No

Low-intervention

No

Rare-disease indication

No

Vulnerable population

No

Funding sources

Probelte Pharma S.L.U.

Trial design

CTIS Part I — objectives, methods, condition coding

Main objective

Scope: Dose response

To establish the optimal therapeutic dose of Beltavac ® with a polymerized
extract of grass mixture administered in a rush regimen for the
treatment of allergic rhinoconjunctivitis.

Secondary objectives 1

1. To assess the effect on specific immunoglobulin serum levels

Conditions and MedDRA coding

Allergic rhinoconjunctivitis caused due to exposure to pollen grasses

Eligibility criteria

Principal inclusion / exclusion criteria as submitted by sponsor

Inclusion criteria 9

1. 1. Signed and dated Informed Consent Form a. by a legally competent participant,
2. 2. Patients (males or females) aged from 18 to 65 years
3. 3. Being in good physical and mental health
4. 4. Confirmed normal renal and liver function, including non-clinically significant deviations outside the reference ranges (< grade 2 according to the FDA Guidance for Industry for preventive Vaccine Trials [FDA 2007] at screening visit. Upon normalization of the out-of-range value(s), the participant will be eligible),
5. 5. Females with childbearing potential (a woman is considered of childbearing potential [WOCBP] according to the CTFG, if she is i.e., fertile, following menarche and until becoming postmenopausal unless becoming permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy) must be willing to use a highly effective method of contraception: a. Oral, intravaginal or transdermal hormonal medical drugs or -devices containing estrogen/progesterone combinations. b. Oral, injectable or implantable hormonal medical drugs or -devices containing progesterone-only. c. Intrauterine device (IUD); d. Intrauterine hormone-releasing system (IUS) e. Bilateral tubal occlusion f. Vasectomized partner (provided that partner is the sole sexual partner of the WOCB trial participant and that the vasectomized partner has received medical assessment of the surgical success) g. Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository It should always be supplemented with the use of a spermicide. h. Sexual abstinence (Defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the participant). or females unable to bear children (i.e., pre-menarche, tubal ligation, hysterectomy, or post-menopausal (a postmenopausal state is defined as no menses for 12 months without an alternative medical cause.),
6. 6. Female participants with childbearing potential must have a negative pregnancy test in serum at visit 1 (before randomization),
7. 7. Having the diagnosis of grass pollen allergy based on all the following criteria: a. A medical history of allergic rhinoconjunctivitis for grass pollen allergens for at least the previous two pollen seasons, b. A medical history of moderate to severe rhinitis for grass pollen allergens for at least the previous two pollen seasons (definition of allergy severity according to ARIA, see Figure 2, c. A positive skin prick test (Beltaprick Test®, SPT - wheal diameter ≥3 mm) to grass pollen allergens, positive control (histamine) wheal ≥3 mm, negative control (NaCl) wheal <2 mm, d. Specific IgE against grass pollen allergens in serum (minimum CAP class 3 or higher, ≥3.5 kU/L), e. Phl p1 and/or Phl p5 specific IgE in serum ≥ 3,5 kU/l, f. A positive CPT at the visit 1, meaning a Total Symptom Score (TSS) ≥ 5 (adjusted with respect to the reference eye), g. Being treated with anti-allergic medication for at least the previous pollen season prior to enrolment
8. 8. For asthmatic participants: confirmed diagnosis of controlled asthma during the treatment period according to Global Initiative for Asthma (GINA) guidelines (steps 1-3, GINA 2023),
9. 9. FEV1 ≥80% of the participant’s reference value or Peak Expiratory Flow (PEF) ≥80% of the participants´ individual optimal value (for asthmatic participants only).

Exclusion criteria 34

1. 1. Simultaneous participation in other clinical trials or previous participation within 30 days before inclusion,
2. 2. Previous immunotherapy with grass pollen allergens within the last 5 years,
3. 3. Ongoing immunotherapy with grass pollen allergens or any other allergens,
4. 4. Participants with acute allergic rhinitis/rhinoconjunctivitis due to other environmental allergens during the CPT performance,
5. 5. Participants with a sensitization to other environmental allergens (i.e., other pollens, house dust mites, cat dander, dog dander or other perennial antigens) when they present relevant symptoms that can interferes the CPT performance,
6. 6. Being in any relationship or dependence with the Sponsor, CRO and/or Investigator
7. 7. Inability to understand instructions/study documents,
8. 8. History of severe systemic reactions and/or anaphylaxis, including food (e.g., peanut, marine animals) or to Hymenoptera venom (e.g., bee, wasp stings) or to medication (e.g., penicillin), etc.,
9. 9. History of hypersensitivity to the excipients of the investigational product or placebo
10. 10. Mild persistent to severe persistent asthma partly controlled or uncontrolled asthma according to GINA guidelines (GINA 2023, (26))
11. 11. Chronic asthma or emphysema, particularly with a forced expiratory volume in 1 second (FEV1) <80% of the participant’s reference value (ECSC) or Peak Expiratory Flow (PEF) <80% of the participants’ individual optimal value,
12. 12. History of a respiratory tract infection and/or exacerbation of asthma within 2 weeks before the screening
13. 13. History of significant renal disease or chronic hepatic disease,
14. 14. Malignant active disease (ongoing or within the five past years),
15. 15. Severe autoimmune disease,
16. 16. Immune defects including immunosuppression, immunopathies,
17. 17. Vaccination during the entire treatment period, except flu and SARS-CoV-2 vaccinations,
18. 18. Use of systemic immunosuppressive medications (e.g., methotrexate or cyclosporine A) or blood transfusion from one month before screening until the end of the trial,
19. 19. General inflammatory, severe acute or chronic inflammatory diseases,
20. 20. Other chronic diseases such as severe congestive heart failure, cardiovascular insufficiency, active gastric ulcer, inflammatory bowel disease, uncontrolled diabetes mellitus, etc.
21. 21. Intake of antidepressant drugs with potent antihistamine properties such as tricyclic antidepressants (e.g., doxepin, amitriptyline, desipramine, imipramine, etc.),
22. 22. Administration or planned administration of anti-IgE antibodies, mast cell stabilizers or anti-leukotriene agents,
23. 23. Intake of beta-blockers,
24. 24. Active tuberculosis,
25. 25. Having any contraindication for the use of adrenaline (including hyperthyroidism),
26. 26. Known positive serology to Human Immunodeficiency Virus-1/2, Hepatitis B Virus or Hepatitis C Virus,
27. 27. Females who are pregnant, lactating, or of child-bearing potential and not using a highly effective contraceptive method,
28. 28. Administration of corticosteroids (systemic or nasal) or of anti-histaminic drugs before the screening visit (V0), as defined in the Table 6: Waiting period for screening; exception made for routine (previously prescribed) control medication for asthmatic participants,
29. 29. Clinically relevant laboratory values, i.e., grade ≥2 according to the FDA Guidance for Industry for preventive Vaccine Trials (FDA 2007) at screening visit. Upon normalization of the out-of-range value(s) participant will be eligible,
30. 30. Participants for who the Investigator believes will not comply with the study protocol (participants with known alcohol or drug abuse or with a history of a serious psychiatric disorder as well as participants unwilling to give informed consent or to abide by the requirements of the protocol).
31. 31. Participants who are committed to an institution by virtue of an order issued either by the judicial or the administrative authorities.
32. 32. Ocular disorders, such as inflammation/infection of the conjunctiva, cornea, or iris and in case of severe dry eye syndrome.
33. 33. Any type of eye surgery in the last 6 months.
34. 34. Ocular surface diseases in which IgE-mediated hypersensitivity is not involved: Sjögren’s syndrome, blepharitis, blepharoconjunctivitis, urban ocular allergy syndrome, dry eye syndrome, giant papillary conjunctivitis after intolerance to contact lenses or foreign bodies.

Endpoints

Primary and secondary outcome measures (English text)

Primary endpoints 1

1. Proportion of patients whose reactivity to the Conjunctival Provocation Test (CPT) with grass extract decreases between baseline and visit 7. It means that the titrated 10 – fold step allergen concentration required to develop a positive response is at least one dose higher

Secondary endpoints 1

1. Serum values of total IgE, grass specific IgE and IgG4 at baseline and final visit. Serum Phl p1 and Phl p5 specific IgE and IgG4 values at baseline and final visit (V0 and V7).

Investigational products

Investigational medicinal products (IMPs), comparators, placebo, auxiliary

Test 3

Placebo 1

Auxiliary 1

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Probelte Pharma S.L.

Sponsor organisation

Probelte Pharma S.L.

Address

Calle Antonio Belmonte Abellan 7

City

Murcia

Postcode

30100

Country

Spain

Scientific contact point

Organisation

Probelte Pharma S.L.

Contact name

Inmaculada Buendía Jiménez

Public contact point

Organisation

Probelte Pharma S.L.

Contact name

Inmaculada Buendía Jiménez

Locations

2 EU/EEA countries · 16 investigational sites

By country

Investigational sites

Results and documents

Annex IV summary of results, Annex V layperson summary, and all documents registered in CTIS for this trial

Documents 13 files

Public protocol annexes, IB summaries, regulatory submissions and post-authorisation documents registered in CTIS.

Application history

1 submissions — initial application plus substantial / non-substantial modifications